<DOC>
	<DOCNO>NCT02164006</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness TGR-1202 combination brentuximab vedotin patient hodgkin 's lymphoma .</brief_summary>
	<brief_title>Novel PI3K Delta Inhibitor TGR-1202 , Combination With Brentuximab Vedotin Hodgkin 's Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Confirmed diagnosis Hodgkin 's Lymphoma Relapsed refractory autologous stem cell transplant ( ASCT ) least two prior multiagent chemotherapy regimens patient candidate ASCT Eastern Cooperative Oncology Group ( ECOG ) score 0 2 Any major surgery , chemotherapy immunotherapy within last 21 day Known hepatitis B virus , hepatitis C virus HIV infection Autologous hematologic stem cell transplant within 3 month study entry . Patients prior Allogeneic hematologic stem cell transplant exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hodgkin 's</keyword>
</DOC>